盐酸埃克替尼治疗晚期非小细胞肺癌患者56例的疗效分析  

Efficacy Analysis of Icotinib Hydrochloride in the Treatment of 56 Patients with Advanced Non-small Cell Lung Cancer

作　　者：周剑建 ZHOU Jian-jian(Department of Infection Surveillance,Affiliated Tumor Hospital of Harbin Medical University,Harbin,Heilongjiang Province,150000 China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院感染监控科,黑龙江哈尔滨150000

出　　处：《系统医学》2020年第24期123-125,共3页Systems Medicine

摘　　要：目的分析盐酸埃克替尼治疗晚期非小细胞肺癌患者的效果。方法研究纳入了56例晚期非小细胞癌患者作为观察组,行常规治疗+盐酸埃克替尼治疗,纳入时间2017年10月-2020年5月,选取同期常规治疗的56例患者作为对照组,比较两组疗效、免疫功能和生活质量。结果观察组中52例患者治疗有效,有效率是92.86%(52例),高于对照组,差异有统计学意义(χ^2=7.670,P<0.05);观察组治疗后CD8+是(20.11±1.87)%,CD4+是(35.88±3.42)%,CD3+是(52.56±5.27)%,优于对照组,差异有统计学意义(t=22.455、8.241、5.202,P<0.05);观察组躯体健康评分(52.34±3.23)分,情感职能评分(48.98±3.82)分,心理健康评分(53.88±3.17)分,社会职能评分(53.87±3.12)分,高于对照组,差异有统计学意义(t=21.027、12.416、12.967、12.023,P<0.05)。结论盐酸埃克替尼治疗晚期非小细胞肺癌效果较好,对患者的免疫损害较小,可以提升其生活质量。Objective To analyze the effect of icotinib hydrochloride in the treatment of patients with advanced non-small cell lung cancer.Methods A total of 56 patients with advanced non-small cell carcinoma(NSCLC)were included as the observation group,who received conventional treatment plus ektinib hydrochloride.The time of inclusion was from October 2017 to May 2020.56 patients who received conventional treatment during the same period were selected as the control group,and the efficacy,immune function and quality of life of the two groups were compared.Results The treatment of 52 patients in the observation group was effective.The effective rate was 92.86%(52 cases),which was higher than that of the control group.The difference was statistically significant(χ^2=7.670,P<0.05);the CD8+of the observation group after treatment was(20.11±1.87))%,CD4+is(35.88±3.42)%,CD3+is(52.56±5.27)%,better than the control group,the difference is statistically significant(t=22.455,8.241,5.202,P<0.05);the physical health score of the observation group(52.34±3.23)points,emotional function score(48.98±3.82)points,mental health score(53.88±3.17)points,social function score(53.87±3.12)points,higher than the control group,the difference is statistically significant(t=21.027,12.416,12.967,12.023,P<0.05).Conclusion Icotinib hydrochloride has a good effect in the treatment of advanced non-small cell lung cancer,has less immune damage to patients,and can improve their quality of life.

关 键 词：盐酸埃克替尼 晚期非小细胞肺癌 治疗效果 免疫损害 生活质量 

分 类 号：R734.2[医药卫生—肿瘤]